Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2026 Mar 12;16:1820675. doi: 10.3389/fonc.2026.1820675

Correction: A systematic review and exploration of clinical application of Liver depression syndrome in breast cancer

Peng Wu 1,2, Siying Mao 3, Qian Zuo 4, Qianqian Guo 1,5,6,*, Qianjun Chen 1,5,7,*
PMCID: PMC13019356  PMID: 41907630

There was a mistake in Table 4 as published. In the fifth row from the bottom of the first column on the left of the table, the original text is “Pale tongue” but it should actually be “Pale white tongue” with one word missing, which is highlighted in below table in red. The corrected Table 4 appears below.

Table 4.

The frequency of tongue manifestations and pulse conditions of Liver depression syndrome evidence in breast cancer.

Tongue manifestations Frequency,
n (%)
Pulse conditions Frequency,
n (%)
Thin, white fur 144 (48) Stringy pulse 123 (41)
Thin, yellow fur 82 (28) Stringy, slippery pulse 83 (28)
Red tongue 70 (23) Stringy, thready pulse 42 (14)
Thin fur 52 (17) Stringy, deep pulse 21 (7)
Pale tongue 43 (14) Stringy, strong pulse 19 (6)
Pink tongue 29 (10) Thready pulse 15 (5)
Dark red tongue 26 (9) Stringy, rapid pulse 14 (5)
Yellow fur 26 (9) Stringy, moderate pulse 9 (3)
Ecchymosis on tongue 25 (8) Hesitant pulse 8 (3)
Dark tongue 15 (5) Rapid pulse 7 (2)
White fur 13 (4) Thready, rapid pulse 5 (2)
White, greasy tongue 12 (4) Slippery pulse 5 (2)
Light yellow coating 11 (4) Weak pulse 5 (2)
Dark purplish tongue 8 (3) Thready, hesitant pulse 4 (1)
Teeth marks tongue 8 (3) Deep, thready pulse 4 (1)
Greasy tongue 7 (2) Stringy, hesitant
pulse
3 (1)
Enlarged tongue 7 (2) Stringy, thready and rapid pulse 3 (1)
Less fur 6 (2) Moderate pulse 3 (1)
Pale white tongue 5 (2) Deep, weak pulse 2 (1)
Thin, greasy coating 4 (1)
Tender red tongue 3 (1)
Purplish sublingual veins 3 (1)
Peeling of tongue 2 (1)

The original version of this article has been updated.

Footnotes

Edited and reviewed by: Zhi-Xiang Xu, University of Alabama at Birmingham, United States

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES